Clinical symptom score and risk factors for predicting post-acute sequelae of SARS-CoV-2 infection in children hospitalized with COVID-19 in Taiwan.

Publication date: May 26, 2026

The clinical features and risk factors of post-acute sequelae of SARS-CoV-2 infection (PASC) in children remain incomplete. This study aims to identify risk factors and evaluate the predictive utility of a clinical scoring system for PASC in pediatric patients previously hospitalized for COVID-19. We conducted a combined retrospective and prospective cohort study at the China Medical University Children’s Hospital in Taiwan, including 143 children aged 3-18 hospitalized for the acute COVID-19 during the Omicron pandemic from April 2022 to July 2023. PASC was assessed through phone calls, online survey, and in-person follow-ups. Data encompassing demographics, clinical presentations, laboratory results, and acute-phase treatment were collected and compared between children with and without PASC. Each child was assigned total clinical scores based on the acute-phase symptoms and treatment. Multivariable logistic regression was used to identify independent predictors and evaluate the model’s performance using the area under the receiver operating characteristic curve (AUC). Among the 143 discharged children, 35. 7% (n = 51) developed PASC. Children with PASC had significantly longer fever duration (3. 2 vs. 2. 6 days, p = 0. 03), lower viral loads (higher RT-PCR Ct values: 17. 1 vs. 14. 2, p = 0. 03) and higher rates of antiviral therapy (19. 6% vs. 6. 5%, p = 0. 02) during the acute phase compared to those without PASC. There were no differences in age, body weight, other laboratory parameters, length of intensive care unit (ICU) stay, bacterial coinfections, and oxygen supplementation between the two groups. Notably, compared to the non-PASC group, the total clinical scores were significantly higher in the PASC group (37. 9 vs. 31. 5, p = 0. 02). After adjusting for covariates, the multivariable prediction model achieved an AUC of 0. 84. This study identified a significant proportion of children developing PASC following hospitalization for acute COVID-19. Longer fever duration, low viral load (high Ct values) and antiviral therapy during the acute phase emerged as potential risk factors. Moreover, the multivariable prediction model and the clinical scoring system may support post-discharge risk stratification and help prioritize follow-up in children hospitalized for COVID-19. Not applicable.

Open Access PDF

Concepts Keywords
April Children
Bacterial Clinical features
Hospitalization COVID-19
July Hospitalization
Taiwan Risk factors

Semantics

Type Source Name
disease MESH post-acute sequelae of SARS-CoV-2 infection
disease MESH COVID-19
disease MESH fever
disease MESH body weight
disease MESH coinfections
drug DRUGBANK Oxygen
disease MESH Infectious Diseases
disease MESH Dis
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Pirenzepine
pathway REACTOME Reproduction
disease MESH included
disease MESH MD1
disease MESH MS4
drug DRUGBANK Methylphenidate
drug DRUGBANK Aspartame
disease MESH Allergy
disease MESH Severe acute respiratory syndrome
disease MESH infection
disease MESH chronic illnesses
disease MESH obesity
disease MESH cardiovascular disease
drug DRUGBANK Huperzine B
disease MESH dehydration
disease MESH hypoxemia
disease MESH febrile seizures
disease MESH cough
disease MESH rhinorrhea
disease MESH sore throat
disease MESH dyspnea
disease MESH vomiting
disease MESH diarrhea
disease MESH seizures
disease MESH anorexia
disease MESH fatigue
disease MESH myalgia
drug DRUGBANK Saquinavir
disease MESH emergency
pathway REACTOME Infectious disease
disease MESH injury
disease MESH cytokine storm
disease MESH pain
drug DRUGBANK Etoperidone
drug DRUGBANK Guanosine
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH SMC
disease MESH syndrome
disease MESH Congenital heart diseases
disease MESH pulmonary hypertension
disease MESH neurologic disorders
disease MESH epilepsy
disease MESH cerebral palsy
disease MESH hypoxic encephalopathy
disease MESH lung diseases
disease MESH bronchopulmonary dysplasia
disease MESH asthma
pathway KEGG Asthma
disease MESH SLE
disease MESH polymyositis
disease MESH acute lymphoblastic leukemia
disease MESH diabetes mellitus
disease MESH rickets
disease MESH pituitary neoplasm
disease MESH atopic dermatitis
drug DRUGBANK Dexamethasone
drug DRUGBANK Immune Globulin Human
disease MESH enteritis
disease MESH bronchitis

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *